Global Liquid Biopsy Market, Initiatives, Funding, Major Deals, 35 Company Profiles and Recent Developments - Forecast to 2027

Global Liquid Biopsy Market, Initiatives, Funding, Major Deals, 35 Company Profiles and Recent Developments - Forecast to 2027

  • September 2020 •
  • 472 pages •
  • Report ID: 5968017 •
  • Format: PDF
The global liquid biopsy market is expected to reach nearly US$ 8.2 Billion by 2027. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. Liquid biopsy aids in planning the required treatment and also check for treatment effectiveness as well as repeated occurrence of tumor during and after the course of cancer treatment. The abilities of liquid biopsy like, easy and minimal invasiveness, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.

The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years. Some of the key factors inhibiting the growth of liquid biopsy market includes, clinical utility challenges, lack of sensitivity and specificity of liquid biopsy tests and unclear reimbursement & regulation scenario.

Recent Developments
• In June 2020, NeoGenomics, Inc. announced the launch of three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases.
• In June 2020, Guardant Health presented new data demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer.
• In January 2020, Personal Genome Diagnostics Inc. partnered with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology
• In November 2019, Lucence Diagnostics Pte Ltd, a genomic medicine company based in Singapore, raised US$ 20 Million in Series A funding.
• In June 2019, Saga Diagnostics, a Lund, Sweden based company raised US$ 4.1 Million in a financing round from Hadean Ventures.
• In February 2019, MDxHealth SA signed an exclusive distribution agreement with LifeLabs to make SelectMDx, the Company’s non-invasive liquid biopsy prostate cancer test, available in Canada
• In August 2018, Bio-Techne Corporation completed its acquisition of Exosome Diagnostics, Inc.

Global Liquid Biopsy Market & Forecast - by Circulating Biomarker
• Based on circulating biomarkers, the global liquid biopsy market is being dominated by Circulating Tumor Cells (CTCs).
• The circulating tumor DNA (ctDNA) is the 2nd largest segment of the liquid biopsy market.
• The cell free DNA (cfDNA) is the third largest segment of the liquid biopsy market.
• The extracellular vesicles (EVs) segment is the fastest growing segment during the forecast period.

Global Liquid Biopsy Market & Forecast - by Product
• The global liquid biopsy market, by product, is being dominated by Kits and Consumables.
• The instruments segment is likely to witness highest growth in the global liquid biopsy market.
• The services segment captured least share of the liquid biopsy market.

Global Liquid Biopsy Market & Forecast - by Application
• The global liquid biopsy market, by application, is being dominated by oncology application.
• Lung cancer and breast cancer accounts for largest share of the liquid biopsy oncology market.
• The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period.

Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application
• On the basis of clinical application, the therapy selection segment is expected to account for largest share of the liquid biopsy market throughout the forecasting period.
• Treatment monitoring captured second highest share of the liquid biopsy market in 2019, being followed by the early cancer screening application.
• Recurrence monitoring captured least share of the liquid biopsy market.

Global Liquid Biopsy Market & Forecast - by End User
• In 2019, Reference laboratories captured largest share of the global liquid biopsy market.
• Hospital and Physician laboratories occupied second highest share of the liquid biopsy market in 2019, being followed by Academic and Research Centers.

Global Liquid Biopsy Market & Forecast - by Sample Type
• Blood is the most widely used sample type and is expected to remain the largest market during the forecasting period as well.
• The urine sample segment is anticipated to witness noticeable growth throughout the forecast period.

Liquid Biopsy Market & Forecast - Regional Analysis
• North America accounted for largest share of the global liquid biopsy market in 2019, followed by Asia Pacific.
• In North America, United States accounted for largest share of the liquid biopsy market.
• In Europe, Germany and France are the leading market for liquid biopsy.
• Asia pacific is likely to be the fastest growing market for liquid biopsy during the forecast period.
• In Asia Pacific, Japan and China are the leading market for liquid biopsy.
• Latin America is the fourth largest market for liquid biopsy, being followed by Middle East & Africa.

This report titled “Global Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives, Funding, Major Deals, 35 Company Profiles and Recent Developments - Forecast to 2027” provides a comprehensive assessment of the fast-evolving, high-growth Global Liquid Biopsy Market.

This 472 Page report with 118 Figures and 7 Tables has been analyzed from 16 viewpoints:
1. Global Liquid Biopsy Market & Forecast (2015 - 2027)
2. Impact of COVID-19 on Global Liquid Biopsy Market
3. Global Liquid Biopsy Market Share & Forecast (2015 - 2027)
4. Global Liquid Biopsy Market & Forecast - by Circulating Biomarker (2015 - 2027)
5. Global Liquid Biopsy Market & Forecast - by Product (2015 - 2027)
6. Global Liquid Biopsy Market & Forecast - by Application (2015 - 2027)
7. Global Liquid Biopsy Oncology Market & Forecast - By Cancer Types (2015 - 2027)
8. Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2015 - 2027)
9. Global Liquid Biopsy Market & Forecast - by End User (2015 - 2027)
10. Global Liquid Biopsy Market & Forecast - by Sample Type (2015 - 2027)
11. Liquid Biopsy Market & Forecast - Regional Analysis (2015 - 2027)
12. Liquid Biopsy Market Share & Forecast - Geographical Analysis (2015 - 2027)
13. Liquid Biopsy Initiatives
14. Liquid Biopsy Companies Financing Details
15. 35 Company Profiles – Recent Developments / Initiatives, Major Deals
16. Global Liquid Biopsy Market - Driving Factors & Challenges

Global Liquid Biopsy Market & Forecast - by Circulating Biomarker
1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Cell-Free DNA (cfDNA)
4. Extracellular Vesicles (EVs)
5. Other Circulating Biomarkers

Global Liquid Biopsy Market & Forecast - by Product
1. Kits and Consumables
2. Instruments
3. Services

Global Liquid Biopsy Market & Forecast - by Application
1. Oncology Application
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Leukaemia
• Others
2. Non-Cancer Application

Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application
1. Therapy Selection
2. Treatment Monitoring
3. Early Cancer Screening
4. Recurrence Monitoring

Global Liquid Biopsy Market & Forecast - by End User
1. Reference Laboratories
2. Hospitals and Physician Laboratories
3. Academic and Research Centers
4. Other End Users

Global Liquid Biopsy Market & Forecast - by Sample Type
1. Blood Sample
2. Urine Sample
3. Other Fluids Sample

Liquid Biopsy Market & Forecast - Regional Analysis
1. North America
• United States
• Canada
2. Asia Pacific
• South Korea
• Japan
• China
• India
• Australia
• Rest of Asia Pacific
3. Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Rest of Europe
4. Middle East & Africa
• UAE
• Saudi Arabia
• Egypt
• Rest of Middle East & Africa
5. Latin America

Liquid Biopsy Market - Company Profiles, Recent Developments / Initiatives, Major Deals
1. Personal Genome Diagnostics
2. Guardant Health, Inc.
3. Pathway Genomics
4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
5. Cardiff Oncology (Previously Trovagene, Inc.)
6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)
7. Biocept, Inc.
8. ANGLE plc
9. MDxHealth
10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
12. Foundation Medicine, Inc
13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
14. Genomic Health (Now Part of Exact Sciences Corp)
15. Myriad Genetics, Inc
16. Thermo Fisher Scientific, Inc
17. QIAGEN NV
18. Bio-Rad Laboratories, Inc
19. Menarini-Silicon Biosystems
20. GRAIL
21. NeoGenomics, Inc.
22. DiaCarta, Inc.
23. OncoCell MDx (Now Immunis.AI)
24. C2i Genomics
25. Biodesix
26. Freenome
27. Inivata
28. CellMax Life
29. Rarecyte Inc.
30. Saga Diagnostics
31. Thrive Earlier Detection Corp.
32. Lucence Diagnostics Pte Ltd
33. Karius, Inc.
34. Clinical Genomics Technologies Pty Ltd (CG)
35. Elypta

Companies Mentioned
1. Personal Genome Diagnostics
2. Guardant Health, Inc.
3. Pathway Genomics
4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
5. Cardiff Oncology (Previously Trovagene, Inc.)
6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)
7. Biocept, Inc.
8. ANGLE plc
9. MDxHealth
10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
12. Foundation Medicine, Inc
13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
14. Genomic Health (Now Part of Exact Sciences Corp)
15. Myriad Genetics, Inc
16. Thermo Fisher Scientific, Inc
17. QIAGEN NV
18. Bio-Rad Laboratories, Inc
19. Menarini-Silicon Biosystems
20. GRAIL
21. NeoGenomics, Inc.
22. DiaCarta, Inc.
23. OncoCell MDx (Now Immunis.AI)
24. C2i Genomics
25. Biodesix
26. Freenome
27. Inivata
28. CellMax Life
29. Rarecyte Inc.
30. Saga Diagnostics
31. Thrive Earlier Detection Corp.
32. Lucence Diagnostics Pte Ltd
33. Karius, Inc.
34. Clinical Genomics Technologies Pty Ltd (CG)
35. Elypta
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.